SCHEMBL6415318

SCHEMBL6415318

N=C1NC(=O)C(=Cc2cccc(C(=O)O)c2)S1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.63
GSK3B P49841 1/20 0.63
TDP1 Q9NUW8 1/20 0.61
MRE11 P49959 1/20 0.56
XDH P47989 3/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 2/20 0.52
CDK2 P24941 1/20 0.52
AKR1B1 P15121 2/20 0.50
CLK1 P49759 1/20 0.49
CLK2 P49760 1/20 0.49
CLK3 P49761 1/20 0.49
DYRK1A Q13627 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
MYC P01106 1/20 0.49
IL1RN P18510 1/20 0.49
ERAP1 Q9NZ08 1/20 0.49
ENPP2 Q13822 1/20 0.48
NAT1 P18440 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415312 1.00 GSK3A (0.63) GSK3AGSK3BTDP1MRE11XDH
SCHEMBL1250449 0.86 TDP1 (0.76) GSK3BTDP1AKR1B1MYCIL1RN
SCHEMBL12892083 0.86 TDP1 (0.76) GSK3BTDP1AKR1B1MYCIL1RN
SCHEMBL1250447 0.86 TDP1 (0.76) GSK3BTDP1AKR1B1MYCIL1RN
SCHEMBL6416668 0.83 MRE11 (0.70) GSK3AGSK3BTDP1MRE11XDH
SCHEMBL6416669 0.83 MRE11 (0.70) GSK3AGSK3BTDP1MRE11XDH
SCHEMBL8186386 0.82 AKR1B1 (0.74) GSK3BTDP1MRE11XDHMEN1
SCHEMBL8186384 0.82 AKR1B1 (0.74) GSK3BTDP1MRE11XDHMEN1
SCHEMBL22971852 0.81 XDH (0.75) GSK3BTDP1MRE11XDHMEN1
SCHEMBL6721235 0.78 GSK3B (1.00) GSK3AGSK3BTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050019825-A9 Common ligand mimics: pseudothiohydantoins TRIAD THERAPEUTICS, INC. 2005-01-27 US disclosed
US-20040009527-A1 Common ligand mimics: pseudothiohydantoins DONG QING (US) 2004-01-15 US disclosed
WO-2003081209-A2 IDENTIFICATION OF LIGANDS FOR A RECEPTOR FAMILY AND RELATED METHODS TRIAD THERAPEUTICS, INC. (US) 2003-10-02 WO disclosed
US-20030180797-A1 Identification of ligands for a receptor family and related methods TRIAD THERAPEUTICS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050019825-A9 Common ligand mimics: pseudothiohydantoins FGFR3, BID, FLT3 GSK3A 3503/4885GSK3B 3537/4885TDP1 4871/4885
US-20040009527-A1 Common ligand mimics: pseudothiohydantoins FGFR3, BID, FLT3 GSK3A 3503/4885GSK3B 3537/4885TDP1 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.